20.84 USD
▲+0.39+7.92%
盘后 19.09 -1.14%
2026-08-03
市值
$2.30B
市盈率
—
EPS
-3.37
股息率
—
52 周区间
13.18 – 34.29
成交量
2.17M
Beta
0.90
目标价
36.13
52W 低 13.1852W 高 34.29
价格走势
公司简介
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o...